Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Pavlicek

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Genome Research|October 28, 2005
Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27Natalay Kouprina, Adam Pavlicek, Vladimir N Noskov, et al.
Plos One|June 30, 2012
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activationNathan V Lee, Maruja E Lira, Adam Pavlicek, et al.
Plos Biology|March 27, 2004
Accelerated evolution of the ASPM gene controlling brain size begins prior to human brain expansionNatalay Kouprina, Adam Pavlicek, Ganeshwaran H Mochida, et al.
Human Mutation|January 12, 2008
Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD)Steven Bentivegna, Jianbiao Zheng, Eugeni Namsaraev, et al.
Genes, Chromosomes & Cancer|June 27, 2012
Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked familiesNatalay Kouprina, Nicholas C O Lee, Adam Pavlicek, et al.
Journal of the National Cancer Institute|September 24, 2014
Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression dataAntonio F Di Narzo, Sabine Tejpar, Simona Rossi, et al.
Nucleic Acid Therapeutics|February 6, 2025
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry RecommendationsPatrik Andersson, Sebastien A Burel, Heather Estrella, et al.
Molecular Cancer Therapeutics|February 8, 2017
Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma GrowthXinqiang Huang, Jill Magnus, Vivek Kaimal, et al.
Molecular Cancer Therapeutics|March 16, 2021
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor TherapyDavid M Briere, Shuai Li, Andrew Calinisan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer modelsCathy C Zhang, Adam Pavlicek, Qin Zhang, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Genome Research|October 28, 2005
Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27Natalay Kouprina, Adam Pavlicek, Vladimir N Noskov, et al.
Plos One|June 30, 2012
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activationNathan V Lee, Maruja E Lira, Adam Pavlicek, et al.
Plos Biology|March 27, 2004
Accelerated evolution of the ASPM gene controlling brain size begins prior to human brain expansionNatalay Kouprina, Adam Pavlicek, Ganeshwaran H Mochida, et al.
Human Mutation|January 12, 2008
Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD)Steven Bentivegna, Jianbiao Zheng, Eugeni Namsaraev, et al.
Genes, Chromosomes & Cancer|June 27, 2012
Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked familiesNatalay Kouprina, Nicholas C O Lee, Adam Pavlicek, et al.
Journal of the National Cancer Institute|September 24, 2014
Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression dataAntonio F Di Narzo, Sabine Tejpar, Simona Rossi, et al.
Nucleic Acid Therapeutics|February 6, 2025
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry RecommendationsPatrik Andersson, Sebastien A Burel, Heather Estrella, et al.
Molecular Cancer Therapeutics|February 8, 2017
Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma GrowthXinqiang Huang, Jill Magnus, Vivek Kaimal, et al.
Molecular Cancer Therapeutics|March 16, 2021
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor TherapyDavid M Briere, Shuai Li, Andrew Calinisan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer modelsCathy C Zhang, Adam Pavlicek, Qin Zhang, et al.
Pageof 3